End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.76 CNY | -0.74% | -2.65% | +9.27% |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 49% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Appliances, Tools & Housewares
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.27% | 419M | - | ||
+25.92% | 29.4B | C | ||
+45.96% | 7.49B | C+ | ||
+79.56% | 6.38B | - | ||
-21.21% | 5.29B | B- | ||
+10.23% | 3.64B | C- | ||
+34.86% | 3.08B | A | ||
+4.80% | 3.07B | B+ | ||
-6.34% | 2.85B | D | ||
+9.50% | 3.11B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603579 Stock
- Ratings Shanghai Rongtai Health Technology Corporation Limited